Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation

Am J Kidney Dis. 2000 Dec;36(6):1226-41. doi: 10.1053/ajkd.2000.19838.

Abstract

Mononuclear cells accumulate in the renal interstitium and contribute to renal injury in proteinuric nephropathies. Angiotensin-converting enzyme (ACE) inhibitors reduce protein trafficking and also lessen renal structural and functional damage. Many proinflammatory genes, including monocyte chemoattractant protein-1 (MCP-1), a chemoattractant for monocytes and T lymphocytes, are transcriptionally regulated by nuclear factor-kappa B (NF-kB). We aimed to study NF-kB activation and MCP-1 expression over time in two models of progressive proteinuric nephropathies (5/6 nephrectomy and passive Heymann nephritis [PHN]) and evaluate the effect of antiproteinuric therapy with an ACE inhibitor on these factors. In both models, increased urinary protein excretion over time was associated with a remarkable increase in NF-kB activity, which was almost completely suppressed by reducing proteinuria with lisinopril. NF-kB activation was paralleled by upregulation of MCP-1 messenger RNA and interstitial accumulation of ED-1-positive monocytes/macrophages and CD8-positive T cells. Lisinopril inhibited MCP-1 upregulation and limited interstitial inflammation. In a group of PHN rats with advanced disease and severe proteinuria, a dose of lisinopril high enough to inhibit renal ACE activity failed to reduce proteinuria and also did not limit NF-kB activation, which was sustained over time, along with MCP-1 gene overexpression and interstitial inflammation. These data suggest that NF-kB is activated in the presence of increased protein traffic, enhancing the nuclear transcription of the MCP-1 gene with potent chemotactic and inflammatory properties. This mechanism may help explain the long-term renal toxicity of filtered proteins.

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Chemokine CCL2
  • Gene Expression Regulation / drug effects
  • Kidney Diseases / drug therapy*
  • NF-kappa B
  • Protein Transport / drug effects
  • Proteinuria / drug therapy*
  • RNA, Messenger

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Chemokine CCL2
  • NF-kappa B
  • RNA, Messenger